PNB 001
Alternative Names: PNB-001Latest Information Update: 28 Jul 2023
At a glance
- Originator PNB Vesper Life Science
- Class Analgesics; Anti-inflammatories; Antivirals; Anxiolytics; Chlorobenzenes; Lactams; Pyrrolidinones
- Mechanism of Action Cholecystokinin A receptor antagonists; Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections
- No development reported Dysmenorrhoea; Inflammatory bowel diseases; Pain; Ulcerative colitis
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Pain in India (SC)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Dysmenorrhoea in India (PO)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Ulcerative-colitis in India (PO)